Lung cancer is the cause of 32% of all male cancer deaths and 25% of all female cancer
deaths. Because the prognosis depends on early diagnosis and staging, continuous …

Since its introduction in 1974, positron emission tomography (PET) has gained widespread
use, especially in diagnosis and staging of lung cancer. In this respect, 18F …

Lung cancer is a common disease and the leading cause of cancer-related mortality, with
non-small cell lung cancer (NSCLC) accounting for the majority of cases. Following …

Positron emission tomography (PET) using [18F]-fluoro-2-deoxy-D-glucose (FDG) as the
radiopharmaceutical agent was introduced in the late 1990s and has been widely used in …

Lung cancer is a common disease and the leading cause of cancer‐related death in many
countries. Precise staging of patients with non‐small‐cell lung cancer plays an important …

Background Lung cancer is one of the most common malignant tumors in the world, and is
the leading cause of cancer-related mortality. Although there are no conclusive data to …

Positron emission tomography (PET) has been studied for a variety of indications in patients
with known or suspected non–small-cell lung cancer (NSCLC). This article discusses the …

Lung cancer is currently the leading cause of cancer-related death in both men and women
in most Western countries. Tumour stage is the strongest prognostic factor and the most …

This article reviews the potential use of positron emission tomography (PET), alone and in
combination with computed tomography, for evaluating the severity of disease in cystic …

Over the past years, positron emission tomography (PET) with fluoro-2-deoxy-d-glucose
(FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been …